BWXT — BWX Technologies, Inc.
Price when we picked it (Jun 8, 2026)
$189.31
Target: $238.00 (+25.7%)
P/E Ratio
50.5
P/E Forward
39.0
Dividend
0.58%
Market Cap
$17.2B
EPS
$3.75
Consensus
Buy
What they do
BWX Technologies, Inc. (NYSE: BWXT) manufactures ultra-high-precision nuclear components. It is, above all, a defense contractor: the sole supplier of the nuclear reactors that propel the U.S. Navy's submarines and aircraft carriers. HQ Lynchburg, Virginia.
Three businesses:
**
- Government Operations / Naval Nuclear — the heart. BWXT designs and builds the naval nuclear reactors for the U.S. Navy. It's a structural monopoly**: the Navy has no other qualified supplier, and the programs (Columbia- and Virginia-class submarines, aircraft carriers) run for decades. Hence the giant backlog (~$8.65 billion) and the revenue predictability.
**
- Advanced Technologies / micro-reactors — small, transportable nuclear reactors. It leads Project Pele**, the Department of Defense micro-reactor built to power remote bases, and participates in advanced-reactor projects for civilian and industrial use.
**
- BWXT Medical — produces radioisotopes** and radiopharmaceuticals used in imaging diagnostics and cancer treatments. It's a high-margin healthcare business with growing demand.
Capital allocation: pays a small dividend (~0.58%, ~$1.08/year) and reinvests in capacity. Leadership: CEO Rex D. Geveden. Q1 2026: revenue $860.2M, EPS $1.12, backlog $8.65 billion.
Why we like it
BWXT at $189.31 means buying the only manufacturer of the reactors that power the U.S. Navy — a monopoly backed by defense budgets — with two growth options thrown in for free (micro-reactors and nuclear medicine). Specific reasons:
- An irreplaceable monopoly: BWXT is the ONLY qualified supplier of U.S. naval reactors. The Navy can't switch suppliers — certifying another one would take decades and billions of dollars. That's a nearly unbreachable moat.
- Defense-shielded revenue: the ~$8.65 billion backlog and 20-30 year submarine/carrier programs provide cash-flow visibility almost no industry has. It doesn't depend on the economic cycle; it depends on the U.S. military budget (which is rising).
- The nuclear renaissance, low-risk version: instead of betting on a reactor startup, you buy the established supplier that already builds military-grade reactors and is expanding into micro-reactors (Project Pele) and civilian power.
- Nuclear medicine (optionality): BWXT Medical rides the theranostics boom — isotopes to detect and treat cancer — a high-margin, structurally growing market.
- AI's hunger for electricity: data centers' appetite for power is re-rating everything nuclear, and BWXT is a core supplier. Analysts: Buy, average target ~$238 (~+26%).
Key Risk
Risks:
- Dependence on the U.S. defense budget — the #1: most revenue comes from the Navy. A military spending cut, a delay in submarine/carrier programs, or a budget fight in Congress hits directly.
- High valuation: at ~50x earnings, the price already assumes growth; if execution disappoints, there's room for a correction.
- Single-customer concentration: when your main customer is one buyer (the U.S. government), you lose pricing power and depend on its agenda.
- Executing complex programs: building nuclear reactors is about as hard and regulated as it gets; cost overruns, delays or quality problems can eat the margin.
- A small dividend (~0.58%): the dividend income is symbolic; the thesis is growth, not income.
- New businesses without proven scale: micro-reactors and nuclear medicine are promising but still small next to the naval business; they'll take time to move the needle.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked BWXT on Jun 8, 2026 at $189.31.
Full Research
BWX Technologies (BWXT) — Full Research
Price: $189.31 | P/E TTM: ~50.5x | Div Yield: ~0.58% | Market Cap: ~$17.2B USD
What is BWXT?
The sole manufacturer of the nuclear reactors that propel the U.S. Navy's submarines and aircraft carriers. A monopoly by design, backed by defense budgets. HQ Lynchburg, Virginia.
3 Businesses
| Segment | What it is | Note |
|---|---|---|
| Naval Nuclear | Reactors for the U.S. Navy (submarines, carriers) | Monopoly, backlog ~$8.65B |
| Advanced Tech / micro-reactors | Project Pele (DoD), advanced reactors | Growth |
| BWXT Medical | Radioisotopes for diagnostics and cancer | High margin |
Q1 2026
| Metric | Q1 2026 |
|---|---|
| Revenue | $860.2M |
| EPS | $1.12 |
| Backlog | $8.65 billion |
Capital Allocation
- Dividend: ~$1.08/year (~0.58%).
- Reinvestment in capacity.
Leadership
- CEO: Rex D. Geveden.
Anchor Fact
Every nuclear submarine and aircraft carrier in the U.S. Navy carries a reactor inside — and there is ONE company in the world authorized to build them: BWXT. The Navy has no 'plan B': certifying another supplier would take decades. That gives BWXT military contracts running 20 or 30 years and an order backlog of ~$8.65 billion, no matter whether the economy rises or falls.
Top 5 Risks
- Dependence on the U.S. defense budget
- High valuation (~50x)
- Single-customer concentration (the government)
- Executing complex nuclear programs
- Symbolic dividend (~0.58%) — the thesis is growth
Analyst Consensus
- Rating: Buy
- Average target: ~$238 (~+26% from $189.31)
The Thesis in One Line
The irreplaceable monopoly on the U.S. Navy's reactors, shielded by defense budgets, with micro-reactors and nuclear medicine as growth options.
Research date: Jun 8, 2026 | Next review: Dec 2026
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.